Dr. Shannon Miller is the Vice President of Operations at Inimmune, where she also leads the company’s immunology R&D team. Prior to serving as VP of Operations, Dr. Miller previously served as an Investigator and Director at Inimmune and held a faculty position at the University of Montana.
Dr. Miller earned her PhD in Immunology from the University of Colorado Anschutz Medical Campus in 2016, where her research focused on HIV pathogenesis. Following her doctoral studies, she joined the Center for Translational Medicine at the University of Montana as a postdoctoral researcher to elucidate the function of innate immune agonists as vaccine adjuvants. In 2019, Dr. Miller joined Inimmune as an Investigator, leading the immunology team while concurrently advancing her academic career as research faculty at the University of Montana. She made the decision to fully dedicate her expertise to Inimmune in early 2023, leading multiple NIH and internally funded projects focused on the use of innate immune agonists in therapeutic areas such as allergy, cancer, and vaccine adjuvants. Dr. Miller led the transition of Inimmune’s lead oncology asset, INI-4001, from preclinical development into a Phase I clinical trial and was promoted to Director in January 2024.
Dr. Miller has established herself as a leader in the field of innate immune agonists, as well as a clear and compelling science communicator. Her leadership, vision, and unwavering commitment to advancing the company’s mission have been pivotal to its success and led to her most recent promotion to VP of Operations in late 2024.
